Handelsbanken Fonder AB Buys New Stake in Celcuity, Inc. $CELC

Handelsbanken Fonder AB purchased a new position in shares of Celcuity, Inc. (NASDAQ:CELC) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 10,500 shares of the company’s stock, valued at approximately $1,099,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Assenagon Asset Management S.A. purchased a new position in Celcuity during the 2nd quarter valued at about $19,683,000. Parallel Advisors LLC purchased a new position in shares of Celcuity in the first quarter valued at approximately $38,000. Janus Henderson Group PLC grew its holdings in shares of Celcuity by 54.8% in the first quarter. Janus Henderson Group PLC now owns 9,600 shares of the company’s stock valued at $1,095,000 after purchasing an additional 3,400 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in Celcuity by 139.1% during the 1st quarter. EverSource Wealth Advisors LLC now owns 820 shares of the company’s stock worth $94,000 after buying an additional 477 shares during the period. Finally, California State Teachers Retirement System lifted its holdings in Celcuity by 91.2% during the 1st quarter. California State Teachers Retirement System now owns 25,580 shares of the company’s stock worth $2,920,000 after buying an additional 12,201 shares in the last quarter. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on CELC. HC Wainwright restated a “buy” rating and issued a $155.00 price target on shares of Celcuity in a research note on Friday, August 14th. Stifel Nicolaus decreased their target price on Celcuity from $175.00 to $150.00 and set a “buy” rating for the company in a report on Friday, August 14th. Wells Fargo & Company lowered their target price on Celcuity from $183.00 to $166.00 and set an “overweight” rating for the company in a research note on Wednesday, June 3rd. Weiss Ratings upgraded Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 4th. Finally, Craig Hallum reiterated a “buy” rating and issued a $178.00 price objective on shares of Celcuity in a research note on Wednesday, July 15th. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $154.55.

Celcuity Stock Performance

Shares of CELC opened at $93.24 on Wednesday. The stock has a 50 day moving average price of $94.00 and a 200 day moving average price of $108.08. The company has a quick ratio of 8.93, a current ratio of 8.93 and a debt-to-equity ratio of 6.04. The company has a market capitalization of $4.55 billion, a price-to-earnings ratio of -21.68 and a beta of 0.21. Celcuity, Inc. has a 52-week low of $44.42 and a 52-week high of $151.02.

Celcuity (NASDAQ:CELC) last released its quarterly earnings data on Thursday, August 13th. The company reported ($1.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.28). Research analysts predict that Celcuity, Inc. will post -4.18 EPS for the current fiscal year.

Celcuity Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.